Today: 8 June 2026
Browse Category

NASDAQ:GRAIL 30 December 2025 - 20 February 2026

GRAIL stock dives nearly 50% after UK Galleri trial misses key goal, raising FDA questions

GRAIL stock dives nearly 50% after UK Galleri trial misses key goal, raising FDA questions

GRAIL shares plunged nearly 50% to $51.00 after a UK trial showed its Galleri blood test missed the main goal of significantly improving early cancer detection. The study’s results complicate prospects for broad screening and reimbursement. Focus now shifts to U.S. regulators and Medicare-linked evidence. GRAIL reported Q4 revenue up 14% to $43.6 million and said its FDA approval submission is under review.
20 February 2026
··
GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL shares dropped 3.3% to $84.95 Tuesday afternoon, extending a two-day slide. An Oregon Health & Science University release highlighted PATHFINDER 2 data and confirmed a first-quarter 2026 FDA submission for Galleri. Investors await management’s Jan. 12 update at the J.P. Morgan Healthcare Conference. The stock is down 7.2% since Friday’s close.
30 December 2025
··

Stock Market Today

  • Felix Industries NSE:FELIX Earnings Show Cash Flow Concerns and Share Dilution
    June 7, 2026, 9:44 PM EDT. Felix Industries Limited (NSE:FELIX) reported a statutory profit of ₹181.4 million but failed to generate free cash flow (FCF), posting a negative FCF of ₹512 million over the past year. The company's accrual ratio stood at 0.47, indicating profits are not matched by cash inflows, which raises concerns about future profitability. Additionally, Felix Industries increased its shares outstanding by 11% in 12 months, diluting earnings per share growth despite a 1,450% rise in net income over three years. This dilution means shareholders' earnings growth is less pronounced, with EPS up 382%. Investors remain cautious amid these financial signals linked to cash flow and shareholder dilution.

Latest articles

Snap Drops 5%—Ad Recovery Eyed Next

Snap Drops 5%—Ad Recovery Eyed Next

8 June 2026
Snap closed Friday at $5.76, down 5.11% amid a broad tech selloff triggered by a strong jobs report and renewed rate-hike worries, but still ended the week up 0.9%. Investors now await U.S. inflation data and CEO Evan Spiegel’s June 16 AWE keynote on Specs, as Snap faces pressure from weak North American ad revenue, tough competition, and activist demands for cost cuts.
Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

8 June 2026
Navitas plunged $5.61 to $25.08 Friday as a $1.3 trillion chip selloff erased Nvidia-driven gains, despite news it issued 3.28 million shares for merger earn-outs and showcased its GaNFast power board at Nvidia’s AI MGX event; investors now face risks from share dilution, sector volatility, and Navitas’s early-stage pivot to high-power AI markets amid ongoing operating losses.
NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

8 June 2026
NIO’s U.S.-listed shares plunged 5.8% Friday, erasing a delivery-led rally, as investors focus on whether June sales can hit the company’s Q2 target after May deliveries rose 62.3% to 37,705. NIO needs 42,939–47,939 June deliveries to meet guidance, with risks from China’s saturated car market and recent price pressure.
HPE Stock Faces AI Rally Test With Monday In Focus

HPE Stock Faces AI Rally Test With Monday In Focus

8 June 2026
Hewlett Packard Enterprise plunged 8.36% Friday to $49.20, capping a three-day slide and erasing gains after a post-earnings surge, even as it raised its fiscal 2026 revenue growth outlook to 29%-33% and boosted non-GAAP EPS guidance, with analysts warning that rapid gains may have priced in too much hope too quickly.
Go toTop